Miquel Gil

Miquel Gil

Auto-generated profile, based on publicly available information

Miquel Gil

Department of Angiology and Vascular Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; Hospital Universitari de Mataró, Mataró, Catalonia, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
Sergi Bellmunt MontoyaSergi Bellmunt Montoya
Sergi Bellmunt Montoya
CRClaudia Riera
Claudia Riera
DGDaniel Gil-Sala
Daniel Gil-Sala
MRManuela Rodríguez
Manuela Rodríguez
MGMarvin García-Reyes
Marvin García-Reyes
SLSecundino Llagostera
Secundino Llagostera

9 October 2020 in Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
PDF file
MMMarc Masana
Marc Masana
LMLucia I. Martinez
Lucia I. Martinez
MGMiquel Gil
Miquel Gil
GBGonzalo Bueno
Gonzalo Bueno
SLSecundino Llagostera
Secundino Llagostera
Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications. We report a 67-year-old-woman admitted for severe acute respiratory syndrome coronavirus 2 infection. Chest CT images showed bilateral ground glass opacities, bilateral pulmonary embolism, right ventricular clot in transit and 2 thoracic aortic mural thrombus. Therapy was initiated with subcutaneous low-molecular-weight heparin, and the patient was discharged at 20 days asymptomatic. Complete resolution of the aortic thrombus was observed in a 1-month surveillance CT angiogram. Our case illustrates vascular complications in a COVID-19 patient and its effective treatment with anticoagulation.

3 June 2026 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
MSMarc Sirvent
Marc Sirvent
CRClaudia Riera
Claudia Riera
MGMiquel Gil
Miquel Gil
XMXavier Martí-Mestre
Xavier Martí-Mestre
VAVicenç Artigas
Vicenç Artigas
Sergi Bellmunt MontoyaSergi Bellmunt Montoya
Sergi Bellmunt Montoya
Plain balloon angioplasty (PBA) remains the standard technique for vessel preparation in peripheral artery disease. This prospective, single centre, single blind, parallel group, superiority randomised trial enrolled chronic limb threatening ischaemia (CLTI) patients with femoropopliteal (FP) lesions. It evaluated whether AngioSculpt scoring balloon (SB) use, compared with PBA, before Luminor drug coated balloon (DCB) angioplasty in FP lesions and CLTI reduces the need for bailout stenting and improves patency without increasing procedural costs. Patients with FP disease and Rutherford category 4 or 5 were randomised to PBA (control) or SB as vessel preparation. Sample size was calculated based on expected bailout stenting rates from previous studies, requiring 39 patients per arm. The primary endpoint was bailout stenting, defined as stent implantation during the index procedure for residual stenosis > 30% or type C dissection (Kobayashi classification). Secondary endpoints included primary patency, defined as duplex ultrasound peak systolic velocity ratio < 2.5 without clinically driven target lesion revascularisation, and procedural cost, defined as the total cost of all balloons and stents used during the index procedure. Eighty-three subjects were enrolled between September 2020 and November 2022 (43 SB, 40 PBA). Mean follow up was 517 ± 272 days. Mean lesion length was 235 ± 134 mm in the SB group and 219 ± 130 mm in the control. Bailout stenting was required in 33% of PBA vs. 5% of SB (p = .003). Overall primary patency was higher in the SB group (91% vs. 70%; p = .035). Procedural costs were €108 lower per patient in the SB cohort (p = .003). In this study, the use of a SB for vessel preparation prior to DCB angioplasty in CLTI patients with FP lesions significantly reduced the need for bailout stenting and was associated with improved primary patency and lower procedural costs compared with PBA. (ClinicalTrials registration ID: NCT07136883).

20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ITI. Tusquets
I. Tusquets
MRM. Ramos
M. Ramos
MGM. Gil
M. Gil
PSP. Sánchez-Rovira
P. Sánchez-Rovira
JMJ. R. Mel
J. R. Mel
Ana-I Velasco-FernándezAna-I Velasco-Fernández
Ana-I Velasco-Fernández
10670 Background: T combined with weekly H confers greater tumor response and survival compared to T monotherapy in P with Her-2 positive MBC. A recent report has demonstrated that H can be administered q3wks. The primary endpoint is to evaluate time to progression (TTP). Sencondary objectives are response rate, overall survival and safety profile. Methods: P cytologically or histologically confirmed of metastatic breast cancer, HER-2 positive (+++ by Herceptest, or FISH positive), age > 18, ECOG PS ≤ 2, and adequate organ function, were included. Prior chemotherapy for MBC or adjuvant anthracycline-based regimen in the previous 6 months was not allowed. Treatment: T 100 mg/m2 iv D1 q3wks for 6 cycles, H 8 mg/kg (cycle 1) and 6 mg/kg (consecutive cycles) iv D1, q3wks. P may receive H monotherapy until PD at the investigator criteria. Results: Over 41 analyzed P, median age was 57 years (29–75); ECOG PS 0–1 95% and ductal carcinoma 88%. Twenty five P received prior chemotherapy. Treatment: 217 cycles of TH (median 6) were administered. After that, 23 P received 189 cycles of H monotherapy (median 5, 1–32). During TH treatment median RDI was 97% for T and 96% for H, and it was 99% during H treatment. Over 33 P for efficacy analysis (2 consent withdrawal, 1 allergic reaction, 1 ongoing and 4 response not confirmed by RECIST criteria), 6 achieved CR and 12 PR, for an ORR of 54.6% (95% CI: 37.6–71.6). Median follow-up time was 11.8 m and median TTP was 8.8 m (95% CI, 1.9–15.6). All P were evaluable for safety. During TH treatment, grade III/IV neutropenia occurred in 16 cycles (7.4 %), 14 of them were febrile neutropenia episodes (6.5%). Other grade III/IV toxicities per cycle were: leucopenia (5.5%), hyperglycemia (2.3%), anorexia (2.3%) and skin (2.3%). During H monotherapy treatment, the only grade III-IV toxicities observed were, skin (1.6%), oedema (1.1%), nail disorders (0.5%) and malaise (4.3%). Six P (14.6%) dropped out due to cardiac toxicity: 5 had LVEF under 50% and one atrial fibrillation. Conclusions: Preliminary results suggest that TH q3wks followed by H as single agent, is an effective regimen for the treatment of P with Her2 positive MBC. No significant financial relationships to disclose.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MVManuel Ramos Vazquez
Manuel Ramos Vazquez
ARAndres Redondo
Andres Redondo
LMLuis Manso
Luis Manso
MGMiquel Gil
Miquel Gil
IGIsabel Garau
Isabel Garau
GLGuillermo Lopez-Vivanco
Guillermo Lopez-Vivanco
E12563 Background: Randomized controlled trials in MBC patients evaluating bevacizumab as first-line treatment showed improvements in tumor response and progression-free survival (PFS) when added to chemotherapy. The aim of the LORENA study was to describe the clinical features, prognosis factors and safety of bevacizumab and chemotherapy treatment for MBC in routine practice. Methods: Observational, multicentre, ambispective study conducted in Spain. The study had a retrospective and a prospective phase. Data were obtained from March 2012 to October 2013. In the retrospective phase, eligible patients were women with metastatic or locally-advanced breast cancer, treated with bevacizumab as a first-line therapy, and progression-free survival for ≥ 12 months. In the prospective phase, patients were followed-up and assessed as per routine clinical practice. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Univariate and multivariate analyses of prognostic factors were performed. Results: 148 women from 38 centers were included. The mean age was 52 (±11) years. Bone, lung and liver were the most frequent metastasis sites. 138 patients were HER2-neg. on diagnosis (data unknown in 10 patients). The mean exposure to bevacizumab was 18 (±11) months. Most patients had objective response, 23% complete response, and 57% partial response. Median OS was 58.2 months and median PFS was 22.7 months. In multivariate analyses, OS was higher in patients with hormonal maintenance therapy (HMT) (p = 0.009; HR = 2.0) and in patients not treated with taxanes before the metastatic diagnosis (p < 0.0001; HR = 3.3); also, PFS was higher in patients with HMT (p = 0.002; HR = 1.8). No adverse events were observed other than those reported previously. Conclusions: Outcomes of OS and PFS suggest a benefit from bevacizumab maintained therapy. HMT was a PFS prognosis factor. HMT and not having been treated with taxanes before the metastatic diagnosis were two independent OS prognosis factors. Our results could provide further evidence supporting the use of bevacizumab as maintenance therapy for MBC patients.